



### **Regional Order Set**

# Clostridium Difficile Infection (CDI) Treatment for Adult Inpatient Orders

	Page 1 of 2	PATIENT LABEL			
Allergies: ☐ None known ☐ Unable to obtain					
List with reactions:					
Confirmed CDI: See page 2 for further CDI definitions Acute onset diarrhea (3 or more loose stools in  • Stool testing positive for toxigenic <i>C. diffice</i> • Pseudomembranous colitis on endoscopy	24 hours) abo cile or detectio	n of toxigenic C.		<u>nd</u> any one	of:
Treatment: (check only one option from list belo	ow)				
First CDI episode: (not meeting criteria for fuln	<del>,                                    </del>				
Non-severe WBC less than 15 x 10°/L and	1. metro	NIDAZOLE 500	mg PO/NG tid	x 10 days <sup>A,B</sup>	
SCr less than or equal to 1.5 x baseline	2. □ vancomycin 125 mg PO/NG qid x 10 days <sup>B,C</sup>				
<b>Severe</b> Any of the following: WBC greater than 15 x 10°/L, SCr greater than 1.5 x baseline or hypoalbuminemia	□ vanco	omycin 125 mg	PO/NG qid x 10	) days <sup>B,C</sup>	
Recurrent CDI episode: (not meeting criteria fo	r fulminant C	DI; consider In	fectious Disea	se consult)	
First recurrence	□ vanco	mycin 125 mg	PO/NG qid x 10	) days <sup>B,C</sup>	
Second recurrence (pulse and taper)	vanco vanco vanco	omycin 125 mg omycin 125 mg omycin 125 mg omycin 125 mg omycin 125 mg	PO/NG BID x 7 PO/NG daily x 7 PO/NG every 2	days, then 7 days, then days x 7 day	ys, then
Third or subsequent recurrence	Consult Infe	ectious Disease	 es		
Fulminant CDI: (any of the following: ileus, tox	ic megacolor	, perforation, h	nypotension or	shock)	
Consult General Surgery, Infectious Disease, a  vancomycin 500 mg PO/NG qid and n  If ileus present, consider adding:  vancomycin 500 mg in 100 mL NS q6f	netroNIDAZO	LE 500 mg IV q	8h x 10 days <sup>B</sup>		
		•	-		
A If no improvement by day 4 or intolerant to PO me B Consider extending to 14 days if unresolved symp C Outpatient prescription requires Pharmacare Spec	otoms by day 1		1011 2		
Other treatments:  • Discontinue antidiarrheals: loperamide, c • Discontinue promotility agents: metoclop • Discontinue laxatives (e.g. sennosides)			pulgite, bismut	th subsalicy	rlate
MRP to review and consider discontinuation of	the following	medications u	nless absolute	ely necessai	ry:
☐ Discontinue antibiotics:	(	☐ Discontinue p	roton pump inhi	bitors (e.g. <b>p</b>	antoprazole
Monitoring:					
<ul> <li>Document stool frequency and consistence</li> </ul>	cy on stool cha	art daily (see 10-	-000-5208)		
☐ Vital signs q h ☐ CBC with di	fferential, elec	trolytes, urea, S	Cr daily x	days	
Physician signature: College 10-111-5354 (IND - VPM/RPD - Appr 06/20) Review by Decer	ID: I mber 2023	Date:	Time:		

~ Do NOT photocopy or alter electronically. Print new copies directly from OurNH Order Set Site ~





#### Regional Order Set

## **Clostridium Difficile Infection (CDI)** Treatment for Adult Inpatient Orders Page 2 of 2 PATIENT LABEL

Allergies: ☐ None known	☐ Unable to obtain
List with reactions:	

#### Asymptomatic *C. difficile* colonization:

Stool testing positive for toxigenic C. difficile without symptoms of C. difficile infection.

This does not require any treatment - up to 10% of the population asymptomatically carries toxigenic C. difficile.

#### Suspected CDI case:

Acute onset of diarrhea (3 or more loose stools in 24 hours) above patient's baseline and not attributed to another cause (e.g. laxatives or enteral feeds).

- Send stool for C. difficile testing
- Consider starting empiric treatment if potentially severe disease (any of WBC greater than 15, SCr greater than 1.5 times baseline, or fulminant disease)

#### **Confirmed CDI case:**

Acute onset of diarrhea (3 or more loose stools in 24 hours) above patient's baseline or ileus

#### And any one of:

- Stool testing positive for toxigenic C. difficile or detection of toxigenic C. difficile
- Pseudomembranous colitis on endoscopy or histopathology

#### Recurrent CDI case:

Recurrence of CDI within 2 to 8 weeks of completion of appropriate treatment for a previous episode which was resolved.

#### Treatment duration:

Consider extending treatment duration to 14 days for patients with unresolved symptoms by day 10.

Do not repeat stool for C. difficile testing if positive within the last 30 days, as patients with CDI may continue to shed C. difficile in the stool for several weeks after responding to a course of therapy.

Probiotics (i.e. Lactobacillus) or cholestyramine are not recommended as adjunctive treatment for or prevention of recurrent CDI as evidence regarding their efficacy is unclear.

Infectious Diseases consultation should be considered for patients who have other infections requiring concomitant antibiotics in setting of C. difficile infection.